{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"53.3","value":"139"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"316"}],"units":"Participants"}],"title":"C2D1 predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"78.3","value":"208"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"277"}],"units":"Participants"}],"title":"C3D1 predose"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"84.8","value":"242"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"243"}],"units":"Participants"}],"title":"C4D1 predose"}],"denoms":[{"counts":[{"groupId":"OG000","value":"342"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Atezolizumab and Paclitaxel"}],"paramType":"MEAN","populationDescription":"PK-evaluable population: all participants who received any dose of Atezolizumab and who have at least one evaluable post-baseline PK sample. For all safety, PK and immunogenicity analyses, participants were grouped according to the treatment actually received, including cases in which atezolizumab was received in error.","reportingStatus":"POSTED","timeFrame":"Pre-dose (0 hours) on Day 1 of Cycles 2-4 and at treatment discontinuation (TD), (approximately 9 months).","title":"Minimum Observed Serum Concentration (Cmin) of Atezolizumab in PK Evaluable Population","type":"SECONDARY","unitOfMeasure":"μg/mL"}